PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

This study is testing a new vaccine-based immunotherapy called PRGN-2009 combined with pembrolizumab (an immune checkpoint drug) in women with cervical cancer that has come back or spread and is no longer responding to pembrolizumab alone. **You may be eligible if...** - You are 18 years or older - You have recurrent or metastatic cervical cancer confirmed by biopsy - Your cancer previously received pembrolizumab and stopped responding - You have received no more than two prior treatments in the recurrent or metastatic setting - Your tumor tests positive for PD-L1 and HPV16/18 - Your cancer can be measured on imaging - Your general health is good enough for treatment **You may NOT be eligible if...** - You have not previously been treated with pembrolizumab - Your cancer does not express PD-L1 or is HPV-negative - You have received more than two prior lines of treatment - You have serious health conditions that would make immunotherapy unsafe Talk to your doctor to see if this trial is right for you.